Related Experiment Video
Updated: Apr 14, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
MET: a new promising biomarker in non-small-cell lung carcinoma
Cristina Pérez-Ramírez1, Marisa Cañadas-Garre, Enrique Jiménez-Varo
1Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda Fuerzas Armadas, 2, 18014 Granada, Spain.
Abstract:
Non-small-cell lung cancer (NSCLC) leads cancer-related deaths worldwide. Mutations in the kinase domain of the EGFR gene provide sensitivity to tyrosine kinase inhibitors (TKI) drugs. TKI show initial response rates over 75% in mutant EGFR-NSCLC patients, although most of these patients acquire resistance to EGFR inhibitors after therapy. EGFR-TKI resistance mechanisms include amplification in MET and its ligand, and also MET mutations. MET signaling dysregulation has been involved in tumor cell growth, survival, migration and invasion, angiogenesis and activation of several pathways, therefore representing an attractive target for anticancer drug development. In this review, we will discuss MET-related mechanisms of EGFR-TKI resistance in NSCLC, as well as the main drugs targeted to inhibit MET pathway.
Insights
Non-small-cell lung cancer (NSCLC) patients resistant to EGFR inhibitors often develop MET pathway alterations. This review explores MET-related resistance mechanisms and targeted therapies for NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Mutations in the epidermal growth factor receptor (EGFR) gene confer sensitivity to tyrosine kinase inhibitors (TKIs).
- Acquired resistance to EGFR-TKIs is a significant clinical challenge in NSCLC treatment.
Purpose of the Study:
- To review MET-related mechanisms driving resistance to EGFR-TKIs in NSCLC.
- To discuss the role of MET signaling in tumor progression and therapeutic targeting.
- To summarize current and emerging drugs targeting the MET pathway for NSCLC.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of genetic alterations and signaling pathways involved in EGFR-TKI resistance.
- Synthesis of information on MET inhibitors and their clinical applications.
Main Results:
- MET amplification, mutations, and ligand overexpression are key mechanisms of acquired resistance to EGFR-TKIs.
- Dysregulated MET signaling promotes NSCLC cell growth, survival, migration, invasion, and angiogenesis.
- Targeting the MET pathway, alone or in combination with EGFR-TKIs, shows promise in overcoming resistance.
Conclusions:
- MET pathway activation is a critical determinant of acquired resistance to EGFR-TKIs in NSCLC.
- Inhibiting the MET pathway represents a rational therapeutic strategy to re-sensitize NSCLC tumors to EGFR-targeted therapy.
- Further research and clinical trials are needed to optimize MET-targeted therapies for NSCLC patients.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
